See more : Aspial Corporation Limited (A30.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Esperion Therapeutics, Inc. (ESPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Esperion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- CynergisTek, Inc. (CTEK) Income Statement Analysis – Financial Results
- Resolute Mining Limited (RSG.L) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Corporation (BIPC.TO) Income Statement Analysis – Financial Results
- iSign Solutions Inc. (ISGN) Income Statement Analysis – Financial Results
- Metrospaces, Inc. (MSPC) Income Statement Analysis – Financial Results
Esperion Therapeutics, Inc. (ESPR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.esperion.com
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.33M | 75.48M | 78.45M | 227.55M | 148.36M | 184.47M | 0.00 | 0.00 | 0.00 | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Cost of Revenue | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265.00K | 258.00K | 252.00K | 236.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 786.00K | 683.22K |
| Gross Profit | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258.00K | -252.00K | -236.00K | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | -784.00K | -683.22K |
| Gross Profit Ratio | 62.81% | 64.27% | 81.88% | 98.95% | -18.36% | 99.86% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -39,200.00% | 0.00% |
| Research & Development | 86.11M | 118.93M | 105.98M | 146.94M | 175.61M | 171.49M | 147.60M | 57.87M | 29.80M | 25.30M | 16.01M | 8.00M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| General & Administrative | 126.92M | 97.78M | 171.29M | 180.32M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.60M | 11.30M | 13.70M | 19.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Other Expenses | 0.00 | 2.65M | 3.98M | 515.00K | 4.06M | 2.78M | 2.19M | 1.55M | 776.00K | 119.00K | 194.01K | -83.65K | -75.81K | 0.00 | 0.00 | 5.00M | 3.20M |
| Operating Expenses | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Cost & Expenses | 271.90M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Interest Income | 0.00 | 2.60M | 112.00K | 600.00K | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100.00K | 198.00K | 376.00K | 520.00K | 270.00K | 936.58K | 1.49M | 577.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 164.00K | 500.00K | 612.00K | 547.00K | 319.00K | 265.00K | 258.00K | 252.00K | 236.00K | 160.00K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |
| EBITDA | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.22M | -26.80M | -25.52M | -11.69M |
| EBITDA Ratio | -129.03% | -234.31% | -283.96% | -53.12% | -60.02% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.45% | 0.00% | 0.00% | 0.00% | 0.00% | -1,086,150.00% | 0.00% |
| Operating Income | -155.56M | -179.50M | -226.73M | -121.40M | -93.10M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.20M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Operating Income Ratio | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.46% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,600.00% | 0.00% |
| Total Other Income/Expenses | -53.69M | -54.16M | -42.38M | -22.16M | -4.06M | 2.78M | 1.99M | 1.17M | 256.00K | -151.00K | -3.33M | -1.54M | -652.97K | -780.00K | 2.39M | -3.80M | 0.00 |
| Income Before Tax | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | 0.00 |
| Income Before Tax Ratio | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,568,550.00% | 0.00% |
| Income Tax Expense | 0.00 | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229.00K | 1.13M | 1.40M | 501.34K | 2.07M | 468.00K | 4.10M | -331.84K |
| Net Income | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Net Income Ratio | -179.87% | -381.34% | -406.42% | -73.04% | -73.48% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,800.00% | 0.00% |
| EPS | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.70 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| Weighted Avg Shares Out | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Weighted Avg Shares Out (Dil) | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered...
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
Esperion Therapeutics (NASDAQ: ESPR ) stock is up on Tuesday after the pharmaceutical company released its earnings report for the first quarter of 2024. The good news from this earnings report includes Q1 revenue of $137.7 million.
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago.
Esperion Reports First Quarter 2024 Financial Results
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased...
Esperion to Participate in Upcoming May Investor Conferences
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the...
Source: https://incomestatements.info
Category: Stock Reports